Literature DB >> 17992608

How the diabetic eye loses vision.

Jaime A Davidson1, Thomas A Ciulla, Janet B McGill, Keri A Kles, Pamela W Anderson.   

Abstract

The objective is to review the most common causes of vision loss in patients with diabetes with the goal of better managing patients with diabetic eye disease. In this review, the causes of vision loss, and the clinical evaluation and management of diabetic retinopathy (DR) and diabetic macular edema (DME) are outlined. Patients with diabetes mellitus have an increased risk of vision loss and blindness. In patients with diabetes, the primary mechanism responsible for vision loss is centrally involved DME or clinically significant macular edema (CSME), defined as vascular leakage resulting in fluid accumulation that affects the center of the macula. DR and DME are thought to result from the effects of excessive blood glucose on the vessels that produces microvascular damage. The progression of DR can be slowed by intensive glycemic and blood pressure control. Severe visual loss from proliferative DR and moderate visual loss from DME can be reduced by laser photocoagulation. DR and DME are diagnosed on dilated retinal examination and confirmed with diagnostic testing. Many experts and associations recommend that patients with diabetes have an yearly, thorough, dilated eye exam. This manuscript describes the case history of a patient with diabetes and vision loss.

Entities:  

Mesh:

Year:  2007        PMID: 17992608     DOI: 10.1007/s12020-007-0040-9

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  31 in total

1.  Retinopathy in diabetes.

Authors:  Donald S Fong; Lloyd Aiello; Thomas W Gardner; George L King; George Blankenship; Jerry D Cavallerano; Fredrick L Ferris; Ronald Klein
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

2.  Screening compliance and visual outcome in diabetes.

Authors:  Gunnar Már Zoega; Thornóra Gunnarsdóttir; Sigríethur Björnsdóttir; Astradur B Hreietharsson; Guethmundur Viggósson; Einar Stefánsson
Journal:  Acta Ophthalmol Scand       Date:  2005-12

3.  Models of open-angle glaucoma prevalence and incidence in the United States.

Authors:  H A Quigley; S Vitale
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-01       Impact factor: 4.799

4.  Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey.

Authors:  J M Tielsch; A Sommer; J Katz; R M Royall; H A Quigley; J Javitt
Journal:  JAMA       Date:  1991-07-17       Impact factor: 56.272

Review 5.  The impact of diabetic retinopathy on health-related quality of life.

Authors:  Sanjay Sharma; Alejandro Oliver-Fernandez; Wei Liu; Patricia Buchholz; John Walt
Journal:  Curr Opin Ophthalmol       Date:  2005-06       Impact factor: 3.761

6.  The prevalence of diabetic retinopathy among adults in the United States.

Authors:  John H Kempen; Benita J O'Colmain; M Cristina Leske; Steven M Haffner; Ronald Klein; Scot E Moss; Hugh R Taylor; Richard F Hamman
Journal:  Arch Ophthalmol       Date:  2004-04

Review 7.  Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales.

Authors:  C P Wilkinson; Frederick L Ferris; Ronald E Klein; Paul P Lee; Carl David Agardh; Matthew Davis; Diana Dills; Anselm Kampik; R Pararajasegaram; Juan T Verdaguer
Journal:  Ophthalmology       Date:  2003-09       Impact factor: 12.079

8.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes.

Authors:  R Klein; B E Klein; S E Moss; K J Cruickshanks
Journal:  Ophthalmology       Date:  1998-10       Impact factor: 12.079

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Longitudinal rates of annual eye examinations of persons with diabetes and chronic eye diseases.

Authors:  Paul P Lee; Zachary W Feldman; Jan Ostermann; Derek S Brown; Frank A Sloan
Journal:  Ophthalmology       Date:  2003-10       Impact factor: 12.079

View more
  15 in total

1.  Kernel regression based segmentation of optical coherence tomography images with diabetic macular edema.

Authors:  Stephanie J Chiu; Michael J Allingham; Priyatham S Mettu; Scott W Cousins; Joseph A Izatt; Sina Farsiu
Journal:  Biomed Opt Express       Date:  2015-03-09       Impact factor: 3.732

2.  Joint retinal layer and fluid segmentation in OCT scans of eyes with severe macular edema using unsupervised representation and auto-context.

Authors:  Alessio Montuoro; Sebastian M Waldstein; Bianca S Gerendas; Ursula Schmidt-Erfurth; Hrvoje Bogunović
Journal:  Biomed Opt Express       Date:  2017-02-27       Impact factor: 3.732

3.  Inhibition of protein kinase C delta attenuates blood-retinal barrier breakdown in diabetic retinopathy.

Authors:  Jeong-Hun Kim; Jin Hyoung Kim; Hyoung-Oh Jun; Young Suk Yu; Kyu-Won Kim
Journal:  Am J Pathol       Date:  2010-01-28       Impact factor: 4.307

Review 4.  Anti-inflammatory therapy for diabetic retinopathy.

Authors:  Wenbo Zhang; Hua Liu; Modesto Rojas; Robert W Caldwell; Ruth B Caldwell
Journal:  Immunotherapy       Date:  2011-05       Impact factor: 4.196

Review 5.  Laser photocoagulation for proliferative diabetic retinopathy.

Authors:  Jennifer R Evans; Manuele Michelessi; Gianni Virgili
Journal:  Cochrane Database Syst Rev       Date:  2014-11-24

6.  Performance of a new reusable insulin pen.

Authors:  Alfred Penfornis
Journal:  Diabetes Technol Ther       Date:  2011-02-03       Impact factor: 6.118

7.  Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices: A Pilot User-Based Study.

Authors:  Udo Stauder; Diplom Enginee; Hina Elton; Alfred Penfornis; Steve Edelman
Journal:  J Diabetes Sci Technol       Date:  2014-01-01

8.  Inflammation and diabetic retinal microvascular complications.

Authors:  Wenbo Zhang; Hua Liu; Mohamed Al-Shabrawey; Robert W Caldwell; Ruth B Caldwell
Journal:  J Cardiovasc Dis Res       Date:  2011-04

9.  Polycomb repressive complex 2 regulates MiR-200b in retinal endothelial cells: potential relevance in diabetic retinopathy.

Authors:  Michael Anthony Ruiz; Biao Feng; Subrata Chakrabarti
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

10.  PPARgamma Agonists: Potential as Therapeutics for Neovascular Retinopathies.

Authors:  Harrihar A Pershadsingh; David M Moore
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.